Tim Pierret

Associate

tim.pierret@icemiller.com

614 462 2294

Tim Pierret is an associate in Ice Miller's Business Group.

Prior to attending law school, Tim worked as a software developer helping create an innovative platform for marketers to develop web applications and cloud-based solutions to allow companies to leverage their data to improve their operations.

Tim earned his juris doctor from Harvard Law School in 2023. While in law school, Tim served as a Project Director for the Harvard Law Entrepreneurship Project and a Line Editor for the *Journal of Law and Technology*. He also participated in the Ames Moot Court competition and worked as a legal intern for United States Attorney's Office in Boston in the Narcotics and Money Laundering Unit.

Tim earned his Bachelor of Science, *cum laude*, in Mechanical Engineering from the University of Notre Dame where he was a member of Tau Beta Pi, the engineering honor society. Tim served as a summer associate at Ice Miller in 2021 and 2022, and officially joined the Firm in September 2023.

Education

- University of Notre Dame (B.S., *cum laude*, 2018)
  - Mechanical Engineering
- Harvard Law School (J.D., 2023)

Admissions

- Indiana
- Ohio

Services & Industries

- Business
- Mergers & Acquisitions

Success Stories

Ice Miller Assists Cellens in Raising $6.5 Million to Advance Physics-Based Test for Bladder Cancer

Ice Miller represented Cellens—a Boston-based cancer diagnostics company pioneering a new mechanobiology and AI-driven platform, BioFeel™, for non-invasive cancer detection, in raising a $6.5 million Series Seed round.

Cellens' technology is a departure from the norm in cancer diagnostics, in which scientists largely rely on molecular markers inside the cell. The company uses atomic force microscopy, which "feels" the stiffness of cells to identify a cancer's biophysical fingerprint rather than its molecular signature. The technology is combined with machine learning algorithms trained on millions of cell interactions.

The financing follows compelling early clinical data generated with leading urologists at Harvard's Brigham and Women's Hospital, showing that the company's urine-based bladder cancer test detected recurrence with strong diagnostic performance, detecting all recurrence cases and achieving an Area under the Curve (AUC) of 88% in an initial prospective clinical study.

The round was led by SOSV, with participation from the Labcorp Venture Fund, KOLON, Blackwood Healthcare Breakthroughs, Tufts University, American Cancer Society BrightEdge, Cancer Fund, TiE Boston Angels, and other strategic investors.

Bladder cancer is among the most common and most expensive cancers to monitor, with an estimated 83,190 new United States cases in 2024 and 800,000 living with the disease nationwide. Because recurrence is frequent, patients undergo repeated invasive cystoscopies, often several times per year. Yet, the majority of these procedures yield negative results, creating significant patient burden and high health care costs. According to SEER-Medicare projections, bladder cancer is expected to reach $11.6 billion in annual United States costs by 2030.

Ice Miller Business partners Dann Bruno and Mai Zymaris represented Cellens in the financing, with assistance from associates Michael Bennett and Tim Pierret. Our Life Sciences practice group has extensive experience working with start-ups to help them with seed-stage funding, intellectual property procurement and counseling, and licensing and strategic alliances.

Click here to read the article.